Oct
6
2020
On demand

Evolving the role of gene editing in cell therapy

Cell therapy is a rapidly evolving field and while there has been some success for delivering novel treatments for liquid tumors, novel approaches are required for overcoming the challenges of cell therapy treatments for solid tumors. One such approach is utilizing gene editing on the underlying primary cell line and improving its persistence, proliferation as well as its ability to survive in the toxic tumor microenvironment.

Attendees will learn about:

  • Scientific rationale for utilizing gene editing in cell therapy
  • The various gene editing technology options available (CRISPR / Base or Prime Editors / ZFNs / TALENs, etc.)
  • Therapeutic approach; Autologous vs Allogeneic
  • Gene editing workflow considerations (equipment, sample tracking, biobanking, etc.)
Dr Jonathan Frampton

Dr Jonathan Frampton

Corporate Development Partner, Horizon Discovery

Dr. Jonathan Frampton is a business development professional who has been working for Horizon Discovery for the past 9 years and currently as their Corporate Development Partner. He is always scouting for exciting novel technology that could complement Horizon’s already extensive gene engineering toolkit. In addition to this he works closely with Horizon’s partners to manage out-licensing opportunities.

Tristan Thwaites

Tristan Thwaites

Lead Technical Scientist, Cell and Gene Therapy Catapult

Tristan is a Lead Technical Scientist at the Cell and Gene Therapy Catapult (CGTC). He has been working in the field of gene editing for >7 years, including researching TALENs and CRISPR across a range of targets. At CGTC he leads the Cellular Engineering program, which is looking to employ gene editing modalities like CRISPR/Cas9 to address industry barriers in advanced therapy manufacture. Prior to joining CGTC, he was head of the High-throughput Gene Editing facility at the Wellcome Trust Sanger Institute. Tristan is a Cell Biologist by training and has obtained his PhD Degree in Cell and Molecular Biology at Imperial College London in 2013. His education and research paths span several areas including host-pathogen interaction, stem cell differentiation and disease modelling, gene editing and viral vector analytics.

Torsten Meissner

Torsten Meissner

Instructor, Department of Surgery, Beth Israel Deaconess Medical Center/Harvard Medical School

Torsten Meissner obtained his PhD in biology at Free University, Berlin and moved on to do postdoctoral research in immunology and stem cell research at Dana-Farber Cancer Institute and Harvard University in Cambridge, Massachusetts. Torsten is currently an Instructor in the Department of Surgery at Beth Israel Deaconess Medical Center in Boston, a Harvard Medical School affiliated research hospital. His research combines genome, cell, and tissue engineering with the overall goal to take down the immune barrier to transplantation. Torsten is currently developing methods to generate immune-silent, living blood vessels from human induced pluripotent stem cells (iPSC) that can be used for disease modeling and vascular reconstruction.

SPEAKERS

Jonathan Frampton
Horizon Discovery at Horizon Discovery
Tristan Thwaites
Lead Technical Scientist at Cell and Gene Therapy Catapult
Torsten Meissner
Postdoctoral Fellow, Department of Stem Cell & Regenerative Biology at Harvard Medical School

You might also like

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
28
Days
14
Hrs
53
Min
Register

Life on a chip - vascularized micro-tumor chips for mimicking clinical...

C Hughes
Chris Hughes
Chris Hughes
CSO at Aracari Biosciences
8 Jun 2022
21
Days
6
Hrs
53
Min
Register

Monitoring of circulating CAR T cells

A Graband,
D Hünecke,
D Bremm
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
13
Days
6
Hrs
53
Min
Register

Discovery to manufacturing: A continuum

A Chang,
T Hitchcock,
B Fry
Audrey Chang
Audrey Chang
Executive Director Quality Control & Analytical Sciences at Charles River Laboratories
Tony Hitchcock
Tony Hitchcock
Technical Director at Charles River Laboratories, Inc
Brian Fry
Brian Fry
Director, Sales - Biologics at Charles River Laboratories
5 April 2022
Watch now

Cell and gene therapy matures: Streamlining and smoothing the path to commercialization

M Hewitt
Matt Hewitt, PhD
Matt Hewitt, PhD
Senior Director, Scientific Services, Cell and Gene Therapy, Charles River Laboratories
11 January 2022
Watch now